Cargando…
Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
BACKGROUND: Regulatory B cells (Bregs), which protect from autoimmunity, are deficient in multiple sclerosis (MS). Novel regulatory B cell subsets CD19(+)CD24(hi)CD38(hi) cells and CD19(+)PD-L1(hi) cells, with disparate regulatory mechanisms have been defined. Alemtuzumab provides a long-lasting sup...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206644/ https://www.ncbi.nlm.nih.gov/pubmed/30373595 http://dx.doi.org/10.1186/s12974-018-1334-y |